Milacemide
![]() | |
| Names | |
|---|---|
| IUPAC name
2-(Pentylamino)acetamide[1] | |
| Identifiers | |
| 76990-56-2 | |
| 3D model (Jmol) | Interactive image Interactive image |
| ChEMBL | ChEMBL75838 |
| ChemSpider | 48376 |
| MeSH | milacemide |
| PubChem | 53569 |
| UNII | 0HXT24RECU |
| |
| |
| Properties | |
| C7H16N2O | |
| Molar mass | 144.22 g·mol−1 |
| log P | 0.754 |
| Related compounds | |
| Related compounds |
Tricine |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Milacemide (INN)[2] is an MAO-B inhibitor and glycine prodrug.[3] It has been studied for its effects on human memory and as a potential treatment for the symptoms of Alzheimer's disease.[4] Early clinical trials did not show positive results however,[3] and the drug is now abandoned.
References
- ↑ "milacemide - Compound Summary". PubChem Compound. USA: National Center for Biotechnology Information. 8 August 2005. Identifiers and Related Records. Retrieved 9 January 2012.
- ↑ "International Nonproprietary Names for Pharmaceutical Substances. Supplement to WHO Chronicle, 1983, Vol. 37, No. 6 (December). Recommended International Nonproprietary Names (Rec. INN): List 23" (PDF). World Health Organization. p. 6. Retrieved 8 January 2016.
- 1 2 Dysken, MW; Mendels, J; LeWitt, P; Reisberg, B; Pomara, N; Wood, J; Skare, S; Fakouhi, JD; Herting, RL (May 1992). "Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.". Journal of the American Geriatrics Society. 40 (5): 503–6. PMID 1634705.
- ↑ Harris, Carol Turkington ; foreword by Joseph R. (2002). The encyclopedia of the brain and brain disorders (2nd ed.). New York, NY: Facts on File. ISBN 0-8160-4774-X.
This article is issued from Wikipedia - version of the 11/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
